DPH1 and acute myeloid leukemia: The clinical success of Tagraxofusp is hampered by acquired deficiencies in the diphthamide synthesis pathway, leading to DPH1 deficiency/downregulation in AML patients causing resistance of leukemic blast cells to the truncated diphtheria toxin domain of the fusion toxin [53,54,55].